Evolus (EOLS) PT Set at $31.00 by Mizuho

Mizuho set a $31.00 price target on Evolus (NASDAQ:EOLS) in a report published on Monday, TipRanks reports. The brokerage currently has a buy rating on the stock.

Other equities analysts have also issued research reports about the company. Cantor Fitzgerald reissued a buy rating and set a $35.00 price objective on shares of Evolus in a research report on Tuesday, April 30th. SunTrust Banks assumed coverage on Evolus in a research report on Wednesday, March 20th. They set a buy rating and a $30.00 price objective for the company. Zacks Investment Research lowered Evolus from a hold rating to a sell rating in a research report on Tuesday, February 5th. Stifel Nicolaus assumed coverage on Evolus in a research report on Monday, January 28th. They set a buy rating and a $27.00 price objective for the company. Finally, HC Wainwright assumed coverage on Evolus in a research report on Thursday, February 14th. They set a buy rating and a $37.00 price objective for the company. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $31.00.

Shares of EOLS stock opened at $16.94 on Monday. Evolus has a 52 week low of $10.22 and a 52 week high of $39.50. The firm has a market capitalization of $463.02 million, a P/E ratio of -10.79 and a beta of 5.01. The company has a quick ratio of 14.52, a current ratio of 14.80 and a debt-to-equity ratio of 0.96.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Tuesday, April 30th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.11). Sell-side analysts anticipate that Evolus will post -3.06 EPS for the current fiscal year.

In related news, Director Simone Blank purchased 628,536 shares of Evolus stock in a transaction dated Monday, May 20th. The stock was purchased at an average cost of $19.25 per share, for a total transaction of $12,099,318.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Corp Alphaeon sold 5,307,940 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $19.25, for a total value of $102,177,845.00. The disclosure for this sale can be found here.

Large investors have recently modified their holdings of the company. Patriot Financial Group Insurance Agency LLC increased its holdings in shares of Evolus by 50.0% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 1,500 shares of the company’s stock valued at $34,000 after acquiring an additional 500 shares in the last quarter. Meeder Asset Management Inc. increased its holdings in shares of Evolus by 48.9% during the first quarter. Meeder Asset Management Inc. now owns 1,732 shares of the company’s stock valued at $39,000 after acquiring an additional 569 shares in the last quarter. Pearl River Capital LLC increased its holdings in shares of Evolus by 217.7% during the first quarter. Pearl River Capital LLC now owns 1,906 shares of the company’s stock valued at $44,000 after acquiring an additional 1,306 shares in the last quarter. BNP Paribas Arbitrage SA increased its holdings in shares of Evolus by 8,877.3% during the first quarter. BNP Paribas Arbitrage SA now owns 1,975 shares of the company’s stock valued at $45,000 after acquiring an additional 1,953 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY bought a new position in shares of Evolus during the first quarter valued at $83,000. Hedge funds and other institutional investors own 19.66% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Story: How does the Beige Book influence monetary policy?

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.